biostudies-literatureUnknown16(1)Tseng HAutologous CAR-T therapies targeting B-cell maturation antigen (BCMA) in relapsed/refractory multiple myeloma (RRMM) have demonstrated therapeutic clinical responses. Here, we present the characterization and interim Phase I data for P-BCMA-ALLO1, a T_SCM-predominant allogeneic CAR-T therapy targeting BCMA in heavily pretreated relapsed/refractory multiple myeloma. Preclinical analyses reveal a strong correlation between CD8⁺ T_SCM phenotype and in vivo potency in mouse xenograft models. In early clinical data (NCT04960579), among the 11 of 33 evaluable patients who received enhanced lymphodepletion, 82% (9/11) responded, with 63.6% (7/11) achieving very good partial response (VGPR) or better. All patients started therapy a median of 1 day after enrollment, wNature communications10050https://www.ebi.ac.uk/biostudies/studies/S-EPMC12644732biostudies-literatureT<sub>SCM</sub>-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial.PMC12644732Namini HShune LKin AMcCaigue JRichter MMarquez KSSolimine BTseng HEskew JDHaag SKwong JMartin CEMcArthur KCoffey MJCranert SACho BSShedlock DJKrasny ARamakrishnan ABacong ACostello CLCoronella JKocoglu MHLoyola ADholaria BBelani RfalseT<sub>SCM</sub>-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial.Autologous CAR-T therapies targeting B-cell maturation antigen (BCMA) in relapsed/refractory multiple myeloma (RRMM) have demonstrated therapeutic clinical responses. Here, we present the characterization and interim Phase I data for P-BCMA-ALLO1, a T_SCM-predominant allogeneic CAR-T therapy targeting BCMA in heavily pretreated relapsed/refractory multiple myeloma. Preclinical analyses reveal a strong correlation between CD8⁺ T_SCM phenotype and in vivo potency in mouse xenograft models. In early clinical data (NCT04960579), among the 11 of 33 evaluable patients who received enhanced lymphodepletion, 82% (9/11) responded, with 63.6% (7/11) achieving very good partial response (VGPR) or better. All patients started therapy a median of 1 day after enrollment, w2025-01-01T00:00:00Z2025 Nov2026-06-06T15:46:40.132Z2026-06-02T03:09:33.197ZS-EPMC126447324128570910.1038/s41467-025-65267-0